Your browser doesn't support javascript.
loading
New progress in the diagnosis and treatment of thiamine responsive megaloblastic anemia syndrome / 中华实用儿科临床杂志
Article in Zh | WPRIM | ID: wpr-930520
Responsible library: WPRO
ABSTRACT
Thiamine responsive megaloblastic anemia syndrome is a rare autosomal recessive disease caused by mutations of the SLC19A2 gene that encodes the high-affinity thiamine transporter-1.Thiamine responsive megaloblastic anemia syndrome involves extensive organs and systems with various clinical manifestations.The typical triad is megaloblastic anemia, non-autoimmune diabetes, and sensorineural deafness.The diagnosis of thiamine responsive megaloblastic anemia syndrome depends on the detection of the pathogenic gene SLC19A2.Thiamine replacement therapy is the first-line treatment.Blood glucose of patients with thiamine responsive megaloblastic anemia syndrome should be comprehensively managed, and hearing aids and cochlear implants can be used to improve the hearing.
Key words
Full text: 1 Database: WPRIM Type of study: Diagnostic_studies Language: Zh Journal: Chinese Journal of Applied Clinical Pediatrics Year: 2022 Document type: Article
Full text: 1 Database: WPRIM Type of study: Diagnostic_studies Language: Zh Journal: Chinese Journal of Applied Clinical Pediatrics Year: 2022 Document type: Article